Antengene's 2025 R&D Day Unveils Progress in Innovative Biotech Programs
Antengene's 2025 R&D Day Showcases Progress and Innovation
Antengene Corporation Limited, a prominent global biotech firm, recently held its 2025 R&D Day, revealing remarkable clinical data and outlining the future directions of its investigational programs. The event took place both in-person at Antengene's Shanghai office and online for global accessibility. Among the highlights, three mid to late-stage clinical programs were presented, focusing on novel therapies for treating solid tumors and autoimmune diseases.
Details of the Key Programs Presented
The key investigational drugs discussed were:
1. ATG-022 - a CLDN18.2 antibody-drug conjugate (ADC)
2. ATG-037 - an oral CD73 small molecule inhibitor
3. ATG-101 - a bispecific antibody targeting PD-L1 and 4-1BB
Furthermore, additional insights were shared on the investigational drug, ATG-125, which targets B7H3 and PD-L1 through a unique
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.